Loading...
The CDC recommends a primary vaccine schedule for pneumococcal conjugate vaccine administration at ages 2, 4, and 6 months. However, the optimal schedule for some high-risk infants has not been determined.
In an industry-funded, multicenter U.K. study, investigators compared antibody responses among 210 premature infants (gestational age <35 weeks) randomized to receive one of three 13-valent pneumococcal conjugate vaccine (PCV13) schedules: reduced (ages 2 and 4 months), accelerated (ages 2, 3, and 4 months), or extended (ages 2, 4, and 6 months). All infants received a 12-month booster dose.
All three schedules resulted in detectable antibody levels after primary series completion, but infants receiving the reduced schedule had lower antibo…